8 episodes

'A Chat with Anat' is a series for ophthalmologists who are interested in improving delivery of care and improved outcomes for patients living with neovascular age-related macular degeneration (nAMD). I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss key topics on patient-focused care. This podcast series is sponsored and organised by Bayer and produced by ApotheCom. This is not intended for UK audiences.

A Chat with Anat ApotheCom

    • Science

'A Chat with Anat' is a series for ophthalmologists who are interested in improving delivery of care and improved outcomes for patients living with neovascular age-related macular degeneration (nAMD). I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss key topics on patient-focused care. This podcast series is sponsored and organised by Bayer and produced by ApotheCom. This is not intended for UK audiences.

    Optimal anti-VEGF therapy regimen

    Optimal anti-VEGF therapy regimen

    In this episode, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney in Australia, and Dr Andrew Chang, Principal Retinal Specialist at the Sydney Retina Clinic and Day Surgery in Australia, share their thoughts on the optimal anti-VEGF therapy regimens to treat retinal vascular diseases, including nAMD and DME. They discuss how the best regimen should be effective in maintaining vision, proactive, individualized to the patient’s needs, and convenient for the patient.
    Using prctical examples from their own clinics, Professor Mitchell and Dr Chang explore how to treat different patients with different levels of starting visual acuity, and how treatments for retinal vascular diseases have changed over time. 
    This podcast is produced in partnership with the Vision Academy, a group of internationally renowned retinal experts who collaborate to provide guidance to the retinal community on clinical challenges in ophthalmology and controversies in care. 
    The Vision Academy viewpoints providing guidance on clinically challenging situations, and other important resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before subscribing.
    If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their thoughts on bilateral retinal disease and treatment, how to optimize treatment of patients with nAMD with macular neovascularization subtypes, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
    SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
     
     Further information on other studies mentioned in this episode:
    ARIES study: Mitchell et al., Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen for Neovascular Age-Related Macular Degeneration. The ARIES Study: A Randomized Clinical Trial https://journals.lww.com/retinajournal/Fulltext/2021/09000/EFFICACY_AND_SAFETY_OF_INTRAVITREAL_AFLIBERCEPT.15.aspx

    July 2023 MA-PFM-OPHT-ALL-1183-1



    The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
    The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    • 28 min
    Reducing the burden of bilateral injections

    Reducing the burden of bilateral injections

    We are delighted to announce that we are expanding A Chat with Anat! We will be partnering with the Vision Academy, a group of retinal experts who collaborate to provide guidance to the retinal community. I will be joined by internationally renowned Vision Academy experts to discuss practice-focused topics covering clinical challenges in ophthalmology and controversies in care. 
    In this episode of A Chat with Anat, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney, and Dr Alex Hunyor, Associate Professor of Ophthalmology at the University of Sydney, discuss pragmatic considerations to reduce the burden of bilateral anti-VEGF injections.
    Professor Mitchell and Dr Hunyor explore how bilateral disease significantly impacts patient quality of life, and how bilateral treatment, especially if the eyes are being treated on different days, can lead to significant burden for patients, caregivers, and for their healthcare system.
    Their conversation also covers how to explain to patients the need for, and risks of, bilateral injections, and how we, as ophthalmologists, can minimise any potential risks with the treatment procedure. 
    The Vision Academy viewpoint providing guidance on bilateral injections, and other important viewpoints and resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
    If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their experiences in navigating the importance of addressing anxiety and depression in our patients with nAMD, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
    SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
    Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources 
    This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

    July 2023 MA-PFM-OPHT-ALL-1181-1
    The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
    The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    • 20 min
    Navigating anxiety and depression in patients with nAMD

    Navigating anxiety and depression in patients with nAMD

    My guest for this episode is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at the University of Manchester and a Consultant Ophthalmologist specializing in the management of retinal disease.

    In this episode, Professor Aslam and I chat about how important it is to consider anxiety and depression when managing our patients with neovascular age-related macular degeneration. Our conversation covers the quick yet effective measures that Professor Aslam has implemented in his own clinic to identify patients with anxiety and depression, with tips for our listeners on how to do the same in their own busy clinics.

    We also discuss how patients with anxiety and depression can be supported and referred for treatment by ensuring we, as ophthalmologists, focus on the patient and not just the retinal disease or its treatment.

    If you enjoyed this episode, please listen to past episodes in the series to hear retinal experts explore how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence, ways to engage and empower our patients, and the evolution of patient expectations in nAMD through the 21st century.

    SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!

    If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/

    Further information on other studies mentioned in this episode:
    POPPIES study: Senra et al., Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol.;  https://www.ajo.com/article/S0002-9394(17)30108-3/fulltext
    Cimarolli et al., Anxiety and depression in patients with advanced macular degeneration: current perspectives. Clin Ophthalmol.; https://www.dovepress.com/anxiety-and-depression-in-patients-with-advanced-macular-degeneration--peer-reviewed-fulltext-article-OPTH
    Sivaprasad et al., Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol.; https://www.dovepress.com/impact-of-injection-therapy-on-retinal-patients-with-diabetic-macular--peer-reviewed-fulltext-article-OPTH
    Weinstein et al., Anxiety in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiol.; https://www.tandfonline.com/doi/abs/10.1080/09286586.2022.2090007
    Discussion guide: https://www.amdbarometer.org/resources 

    This podcast ser
    The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
    The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    • 16 min
    Exploring the research gap of patient perspectives

    Exploring the research gap of patient perspectives

    My guest for this episode is Professor Richard Gale, Professor of Ophthalmology at Hull York Medical School, University of York, UK, and Honorary Consultant Medical Ophthalmologist at the National Health Service’s York Teaching Hospital.

    In this episode, Richard and I will chat about how patients’ emotions, experiences, and perceptions related to anti-vascular endothelial growth factor (anti-VEGF) treatment can influence their treatment adherence and persistence. Despite this, the patient’s perspective is often not considered during the clinical management of neovascular age-related macular degeneration. To tackle this issue, Richard gives us some of his top tips to try in our busy clinics.

    We discuss a systematic literature review article recently published in Acta Ophthalmologica, which was authored by a group of international experts including Richard and myself. Find out more here: https://doi.org/10.1111/aos.15201

    If you enjoyed this episode, go back and listen to our first episode with Richard, where we chat about how to further motivate our patients to be adherent, or try some of the past episodes to hear other retinal experts delve into ways to engage and empower our patients, and explore a history of patient expectations in nAMD through the 21st century.

    SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!

    If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/ 

    Further information on other studies mentioned in this episode:
    ANCHOR study: https://doi.org/10.1016/j.ophtha.2008.10.018
    MARINA study: https://doi.org/10.1016/j.ophtha.2006.10.045
    Prevalence and risk factors for depressive symptoms in patients with nAMD; Australian study: https://doi.org/10.1111/aos.14635

    This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences.

    This is not intended for UK audiences.

    Speaker disclosures:
    Professor Anat Loewenstein
    Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
     
    Professor Richard Gale:
    Consultancy, Research Grants: Alimera, Allergan, Bayer, Novartis, Roche
    The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
    The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    • 17 min
    Evolution of patient expectations in nAMD through the 21st century

    Evolution of patient expectations in nAMD through the 21st century

    My guest for this episode is Professor Paul Mitchell, Emeritus Professor of Ophthalmology at the University of Sydney, Consultant Ophthalmologist at the Western Sydney Local Health District, and Principal of Sydney West Retina Pty Ltd in Australia.

    As treatment for neovascular age-related macular degeneration (nAMD) has evolved through the 21st century, so have the expectations of our patients. Paul joins me to chat about how developments in treatment modalities and regimens led to the evolution of patient expectations following diagnosis of nAMD, and what we can expect for our patients in the future.

    If you enjoyed this episode, try some of our past episodes to hear other retinal experts delve into ways in which we can engage and empower our patients, how to further motivate our patients to be adherent, and how clinic organization can be used to improve adherence and persistence.

    SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!

    If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/

    Further information on studies mentioned in this episode:
    Blue Mountains Eye study (https://doi.org/10.1016/S0161-6420(95)30846-9)
    MARINA study (https://doi.org/10.1056/NEJMoa054481)
    ANCHOR study (https://doi.org/10.1016/j.ophtha.2008.10.018)
    LUCAS study (https://doi.org/10.1016/j.ophtha.2014.07.041)
    ALTAIR study (https://doi.org/10.1007/s12325-020-01236-x)
    ARIES study (https://doi.org/10.1097/IAE.0000000000003128)
    HOME study (https://doi.org/10.1016/j.cct.2014.02.003)
    Algorithm for suspending anti-VEGF treatment in cases of futility (https://doi.org/10.1097/IAE.0000000000002713)

    This is not intended for UK audiences.

    Speaker disclosures:
    Professor Anat Loewenstein
    Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
    Professor Paul Mitchell
    Consultancy: Allergan, Bayer, and Novartis
    The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
    The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    • 17 min
    Ways to engage with patients to enable realistic expectation-setting

    Ways to engage with patients to enable realistic expectation-setting

    My guest is Dr. Jane Barratt, Secretary General of the International Federation on Ageing. In this episode, Jane and I discuss ways in which we can improve our communication with our patients to enable realistic expectation-setting. We also speak about how we can meaningfully engage with, and empower, our patients to support them in managing their nAMD.

    This is not intended for UK audiences.

    Speaker disclosures:
    Professor Anat Loewenstein
    Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
    The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
    The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

    • 19 min

Top Podcasts In Science

Hidden Brain, Shankar Vedantam
WNYC Studios
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Alie Ward
Neil deGrasse Tyson
Sam Harris